期刊文献+

氨氯吡咪诱导卵巢癌细胞凋亡 被引量:1

Apoptosis of ovarian carcinoma cell line induced by amiloride
原文传递
导出
摘要 目的观察利尿药氨氯吡咪(amiloride)诱导卵巢癌细胞凋亡及其可能的机理。方法用光镜及荧光显微镜从形态上了解凋亡的发生,用琼脂糖凝胶电泳进一步检测发生凋亡的特征性DNA降解。流式细胞术定量分析用不同剂量氨氯吡咪处理的卵巢癌细胞诱导的凋亡发生率,同时检测被处理细胞细胞内pH。结果氨氯吡咪处理的卵巢癌细胞在形态学上显示出凋亡细胞的特征,琼脂糖凝胶电泳显示特征性DNA阶梯图。流式细胞术检测表明,0.01~5μmol/L氨氯吡咪能诱导18.7%~61.1%卵巢癌细胞发生凋亡,凋亡发生随用药剂量及药物作用时间增加而增多。氨氯吡咪处理的卵巢癌细胞细胞内pH值降低,并出现一群酸化细胞,经分选而分离出的酸化细胞逐渐表现出染色质的浓缩、致密及DNA降解等凋亡特征。这群酸化细胞与凋亡细胞有很好的相关性(r=0.96)。结论氨氯吡咪能诱导卵巢癌细胞凋亡,可能与其降低细胞内pH有关。 Objective To investigate induction of apoptosis and its possible mechanism in amiloride treated ovarian carcinoma cell line. Methods Morphological changes of apoptotic cells were investigated by light and fluorescence microsopy. DNA fragmentation was analysed by agarose gel electrophoresis. In addition, the number of hypodiploid cells (apoptotic cells) was quantitatively assessed by flow cytometry and intracellular pH was also analysed. Results Amiloride treated ovarian carcinoma cells showed morphological characateristics of apoptosis. A ladder like pattern of DNA fragmentation was demonstrated on agarose gel electrophoresis. Amiloride at 0.01~5 μmol/L could induce apoptosis in 18.7%~61.6% of ovarian carcinoma cells. The apoptosis inducing effect of amiloride was dose and time dependent. In addition, amiloride induced intracellular acidification in a subpopulation of the treated cells. Furthermore, these isolated acidified cells revealed chromatin condensation as well as DNA degradation with characteristics of apoptosis. There was good correlation between apoptotic cells and acidic cells. Conclusion Amiloride triggers apoptosis of ovarian carcinoma cells; intracellular acidification may be involved in the mechanism of apoptosis.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 1999年第1期22-24,共3页 Chinese Journal of Oncology
基金 国家自然科学基金
关键词 卵巢肿瘤 氨氯吡咪 细胞凋亡 Ovarian neoplasms Amiloride Apoptosis
  • 相关文献

参考文献2

  • 1Wei Yuquan,Cancer Immunol Immunother,1995年,40卷,73页
  • 2Wei Yuquan,Cancer Res,1994年,54卷,4952页

同被引文献20

  • 1司徒镇强,吴军正,主编.细胞培养.第1版.西安:世界图书出版公司,1996,134-135.
  • 2David LS,Robert DC,Lealic AL,主编.细胞实验指南.黄培堂,主译.第1版.北京:科学出版社,2001.113-114
  • 3Reinecke P, Knopf C, Schmitz M, et al. Growth inhibitory effects of paclitaxel on human epithelioid sarcoma in vitro: heterogeneity of response and the multidrug resistance phenotype. Cancer, 2000, 88: 1614-1622.
  • 4Swanson PE, Carroll SB, Zhang XF, et al. Spontaneous prematurechromosome condensation, micronucleus formation, and non-apop-totic cell death in heated HeLa S3 cells: ultrastructural observations. Am J Pathol, 1995, 146: 963-971.
  • 5Mross K, Hollander N, Hauns B, et al. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol, 2000, 45:463 -470.
  • 6Nannan Panday VR, de Wit R, Schornagel JH, et al. Pharmacoki netics of paclitaxel administered in combination with cisplatin etoposide and bleomycin in patients with advanced solid tumours.Cancer Chemother Pharmacol, 1999, 44: 349-353.
  • 7Bhalla KN, Kumar GN, Walle UK, et al. Phase Ⅰ and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplat inum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res, 1999, 5: 1723-1730.
  • 8Maier-Lenz H, Hauns B, Haering B, et al. Phase Ⅰ study of paclitaxel administered as a l-hour infusion: toxicity and pharmacoki netics. Semin Oncol, 1997, 24 (6 Suppl 19): 16-19.
  • 9Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc, 1994, 69: 341-345.
  • 10Kumar N. Taxol-induced polymerization of purified tubulin: mecha nism of action. J Biol Chem, 1981, 256: 10435-10441.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部